Loading...
Sproutly Canada Inc.
SRUTF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $0.00 in Q3 2022 to $0.00 in Q2 2023. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $0.00 in Q2 2023, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income rose to $0.00, keeping EPS at $0.00. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan